Hojun Choi

Dr. Hojun Choi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Open access
PDF file
HCHojun Choi
Hojun Choi
YCYoorim Choi
Yoorim Choi
HYHwa Young Yim
Hwa Young Yim
AMAmin Mirzaaghasi
Amin Mirzaaghasi
JYJae-Kwang Yoo
Jae-Kwang Yoo
Chulhee ChoiChulhee Choi
Chulhee Choi
Exosomes are cell-secreted nano-sized vesicles which deliver diverse biological molecules for intercellular communication. Due to their therapeutic potential, exosomes have been engineered in numerous ways for efficient delivery of active pharmaceutical ingredients to various target organs, tissues, and cells. In vivo administered exosomes are normally delivered to the liver, spleen, kidney, lung, and gastrointestinal tract and show rapid clearance from the blood circulation after systemic injection. The biodistribution and pharmacokinetics (PK) of exosomes can be modulated by engineering various factors such as cellular origin and membrane protein composition of exosomes. Recent advances accentuate the potential of targeted delivery of engineered exosomes even to the most challenging organs including the central nervous system. Major breakthroughs have been made related to various imaging techniques for monitoring in vivo biodistribution and PK of exosomes, as well as exosomal surface engineering technologies for inducing targetability. For inducing targeted delivery, therapeutic exosomes can be engineered to express various targeting moieties via direct modification methods such as chemically modifying exosomal surfaces with covalent/non-covalent bonds, or via indirect modification methods by genetically engineering exosome-producing cells. In this review, we describe the current knowledge of biodistribution and PK of exosomes, factors determining the targetability and organotropism of exosomes, and imaging technologies to monitor in vivo administered exosomes. In addition, we highlight recent advances in strategies for inducing targeted delivery of exosomes to specific organs and cells.

25 April 2022 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
SASo-Hee Ahn
So-Hee Ahn
SRSeung-Wook Ryu
Seung-Wook Ryu
HCHojun Choi
Hojun Choi
SYSangmin You
Sangmin You
JPJun Park
Jun Park
Chulhee ChoiChulhee Choi
Chulhee Choi
So-Hee Ahn, Seung-Wook Ryu, Hojun Choi, Sangmin You, Jun Park, and Chulhee Choi. Mol. Cells 2022;45:284-90. https://doi.org/10.14348/molcells.2022.2033

10 April 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
HCHojun Choi
Hojun Choi
YKYoungeun Kim
Youngeun Kim
AMAmin Mirzaaghasi
Amin Mirzaaghasi
JHJaenyoung Heo
Jaenyoung Heo
YKYu Na Kim
Yu Na Kim
Chulhee ChoiChulhee Choi
Chulhee Choi
Next generation exosome-based therapy can protect against systemic inflammation and sepsis-induced death.

18 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HCHojun Choi
Hojun Choi
HCHojun Choi
Hojun Choi
DKDae-Hwan Kim
Dae-Hwan Kim
BOByung-Koo Oh
Byung-Koo Oh
HYHwayoung Yim
Hwayoung Yim
Chulhee ChoiChulhee Choi
Chulhee Choi
Delivering therapeutics to the central nervous system (CNS) is difficult because of the blood–brain barrier (BBB). Therapeutic delivery across the tight junctions of the BBB can be achieved through various endogenous transportation mechanisms. Receptor-mediated transcytosis (RMT) is one of the most widely investigated and used methods. Drugs can hijack RMT by expressing specific ligands that bind to receptors mediating transcytosis, such as the transferrin receptor (TfR), low-density lipoprotein receptor (LDLR), and insulin receptor (INSR). Cell-penetrating peptides and viral components originating from neurotropic viruses can also be utilized for the efficient BBB crossing of therapeutics. Exosomes, or small extracellular vesicles, have gained attention as natural nanoparticles for treating CNS diseases, owing to their potential for natural BBB crossing and broad surface engineering capability. RMT-mediated transport of exosomes expressing ligands such as LDLR-targeting apolipoprotein B has shown promising results. Although surface-modified exosomes possessing brain targetability have shown enhanced CNS delivery in preclinical studies, the successful development of clinically approved exosome therapeutics for CNS diseases requires the establishment of quantitative and qualitative methods for monitoring exosomal delivery to the brain parenchyma in vivo as well as elucidation of the mechanisms underlying the BBB crossing of surface-modified exosomes.

30 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
CLCaixuan Liu
Caixuan Liu
KWKejia Wu
Kejia Wu
HCHojun Choi
Hojun Choi
HHHannah L. Han
Hannah L. Han
XZXueli Zhang
Xueli Zhang
DBDavid Baker
David Baker
Proteins that bind to intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) with high affinity and specificity could be useful for therapeutic and diagnostic applications1,2,3,4. However, a general methodology for targeting IDPs or IDRs has yet to be developed. Here we show that starting only from the target sequence of the input, and freely sampling both target and binding protein conformations, RFdiffusion5 can generate binders to IDPs and IDRs in a wide range of conformations. We used this approach to generate binders to the IDPs amylin, C-peptide, VP48 and BRCA1_ARATH in diverse conformations with a dissociation constant (Kd) ranging from 3 to 100 nM. For the IDRs G3BP1, common cytokine receptor γ-chain (IL-2RG) and prion protein, we diffused binders to β-strand conformations of the targets, obtaining Kd between 10 and 100 nM. Fluorescence imaging experiments show that the binders bind to their respective targets in cells. The G3BP1 binder disrupts stress granule formation in cells, and the amylin binder inhibits amyloid fibril formation and dissociates existing fibres, enables targeting of both monomeric and fibrillar amylin to lysosomes, and increases the sensitivity of mass spectrometry-based amylin detection. Our approach should be useful for creating binders to flexible IDPs or IDRs spanning a wide range of intrinsic conformational preferences.

24 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HCHojun Choi
Hojun Choi
명8명윤 870904
명윤 870904
DKDae-Hwan Kim
Dae-Hwan Kim
HYHanoul Yun
Hanoul Yun
BOByung-Koo Oh
Byung-Koo Oh
Chulhee ChoiChulhee Choi
Chulhee Choi
For the successful clinical advancement of exosome therapeutics, the biodistribution and pharmacokinetic profile of exogenous exosomes in various animal models must be determined. Compared with fluorescence or bioluminescence imaging, radionuclide imaging confers multiple advantages for the in vivo tracking of biomolecular therapeutics because of its excellent sensitivity for deep tissue imaging and potential for quantitative measurement. Herein, we assessed the quantitative biodistribution and pharmacokinetics of good manufacturing practice-grade therapeutic exosomes labeled with zirconium-89 (89Zr) after systemic intravenous administration in mice and rats. Quantitative biodistribution analysis by positron emission tomography/computed tomography and gamma counting in mice and rats revealed that the total 89Zr signals in the organs were lower in rats than in mice, suggesting a higher excretion rate of exosomes in rats. A prolonged 89Zr signal for up to 7 days in most organs indicated that substantial amounts of exosomes were taken up by the parenchymal cells in those organs, highlighting the therapeutic potential of exosomes for the intracellular delivery of therapeutics. Exosomes were mainly distributed in the liver and to a lesser extent in the spleen, while a moderately distributed in the kidney, lung, stomach, intestine, urinary bladder, brain, and heart. Exosomes were rapidly cleared from the blood circulation, with a rate greater than that of free 89Zr, indicating that exosomes might be rapidly taken up by cells and tissues.